In conclusion, rhoifolin regulates the AKT/JNK/caspase-3 and TGF-β2/SMAD2 signaling pathways, which may contribute to its anti-pancreatic cancer effects. The gene discussed is SMAD2; the disease is familial pancreatic carcinoma.